Betaxolol Hydrochloride
If you find any inaccurate information, please let us know by providing your feedback here

This article is compiled based on the United States Pharmacopeia (USP) – 2025 Edition
Issued and maintained by the United States Pharmacopeial Convention (USP)
C₁₈H₂₉NO₃ · HCl 343.89
2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]-, hydrochloride, (±)-;
(±)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride
CAS RN®: 63659-19-8; UNII: 6X97D2XT0O.
1 DEFINITION
Betaxolol Hydrochloride contains NLT 98.0% and NMT 102.0% of betaxolol hydrochloride (C₁₈H₂₉NO₃ · HCl), calculated on the dried basis.
2 IDENTIFICATION
A. Spectroscopic Identification Tests 〈197〉, Infrared Spectroscopy: 197K
B. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.
C. Identification Tests—General 〈191〉, Chemical Identification Tests, Chloride
Analysis: Proceed as directed for amine hydrochlorides. (USP 1-May-2021)
Acceptance criteria: Meets the requirements
3 ASSAY
Procedure
Buffer: 3.4 g/L of monobasic potassium phosphate in water, adjusted with phosphoric acid to a pH of 3.0
Mobile phase: Acetonitrile, methanol, and Buffer (175:175:650)
Standard solution: 1 mg/mL of USP Betaxolol Hydrochloride RS in Mobile phase. Sonicate if necessary.
Sample solution: 1 mg/mL of Betaxolol Hydrochloride in Mobile phase. Sonicate if necessary.
Chromatographic system
(See Chromatography 〈621〉, System Suitability.)
Mode: LC
Detector: UV 222 nm
Column: 4.6-mm × 25-cm; 5-µm packing L7
Flow rate: 1.5 mL/min
Injection volume: 10 µL
System suitability
Sample: Standard solution
Suitability requirements
Tailing factor: NMT 3.0
Relative standard deviation: NMT 0.73%
Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of betaxolol hydrochloride (C₁₈H₂₉NO₃ · HCl) in the portion of Betaxolol Hydrochloride taken:
Result = (rᵤ/rₛ) × (Cₛ/Cᵤ) × 100
rᵤ = peak response from the Sample solution
rₛ = peak response from the Standard solution
Cₛ = concentration of USP Betaxolol Hydrochloride RS in the Standard solution (mg/mL)
Cᵤ = concentration of Betaxolol Hydrochloride in the Sample solution (mg/mL)
Acceptance criteria: 98.0%–102.0% on the dried basis
4 IMPURITIES
Residue on Ignition 〈281〉: NMT 0.1%
Organic Impurities
Buffer, Mobile phase, Sample solution, and Chromatographic system: Proceed as directed in the Assay.
System suitability solution: 1 mg/mL of USP Betaxolol Hydrochloride RS and 30 µg/mL of USP Betaxolol Related Compound A RS in Mobile phase
Standard solution: 0.003 mg/mL of USP Betaxolol Hydrochloride RS in Mobile phase
System suitability
Samples: System suitability solution and Standard solution
[Note—The relative retention times for betaxolol related compound A and betaxolol are 0.9 and 1.0, respectively.]
Suitability requirements
Resolution: NLT 2.0 between the betaxolol related compound A and betaxolol peaks, System suitability solution
Relative standard deviation: NMT 5.0%, Standard solution
Analysis
Samples: Standard solution and Sample solution
Identify the impurities in the Sample solution on the basis of the relative retention times in Table 1.
Calculate the percentage of each impurity in the portion of Betaxolol Hydrochloride taken:
Result = (rᵤ/rₛ) × (Cₛ/Cᵤ) × (1/F) × 100
rᵤ = peak response of each impurity from the Sample solution
rₛ = peak response of betaxolol from the Standard solution
Cₛ = concentration of USP Betaxolol Hydrochloride RS in the Standard solution (mg/mL)
Cᵤ = concentration of Betaxolol Hydrochloride in the Sample solution (mg/mL)
F = relative response factor for each individual impurity (see Table 1)
Acceptance criteria: See Table 1.
| Name | Relative Retention Time | Relative Response Factor | Acceptance Criteria, NMT (%) |
| Betaxolol hydroxyethyl analog (a) | 0.3 | 1.3 | 0.5 |
| Betaxolol related compound A (b) | 0.9 | 1.2 | 0.5 |
| Betaxolol | 1.0 | 1.0 | — |
| Betaxolol phenol analog (c) | 1.6 | 1.3 | 0.5 |
| Betaxolol open chain analog (d) | 1.7 | 0.95 | 0.5 |
| Betaxolol oxirane analog (e) | 3.7 | 1.3 | 0.5 |
| Any unspecified impurity | — | 1.0 | 0.10 |
| Total impurities | — | — | 1.0 |
a. 1-[4-(2-Hydroxyethyl)phenoxy]-3-(isopropylamino)propan-2-ol.
b. 1-(4-Ethylphenoxy)-3-(isopropylamino)propan-2-ol.
c. 4-[2-(Cyclopropylmethoxy)ethyl]phenol.
d. 1-[4-(2-Butoxyethyl)phenoxy]-3-(isopropylamino)propan-2-ol.
e. 2-({[4-(2-Cyclopropylmethoxy)ethyl]phenoxy}methyl)oxirane.
5 SPECIFIC TESTS
pH 〈791〉
Sample solution: 20 mg/mL
Acceptance criteria: 4.5–6.5
Loss on Drying 〈731〉
Analysis: Dry under vacuum at 65° for 2 h.
Acceptance criteria: NMT 1.0%
6 ADDITIONAL REQUIREMENTS
Packaging and Storage: Preserve in tight containers. Store at room temperature.
USP Reference Standards 〈11〉
USP Betaxolol Hydrochloride RS
USP Betaxolol Related Compound A RS
1-(4-Ethylphenoxy)-3-(isopropylamino)propan-2-ol.
C₁₄H₂₁NO₂ 237.34

